BioInvent focuses on the discovery and development of antibody-based drugs against cancer. The Company's lead drug candidate is BI-1206, a human antibody targeting CD32b, an immunosuppressive protein that is expressed in patients with B-cell cancers. The BI-1206 drug is in Phase I/II clinical trials currently ongoing in patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells and tumour-associated myeloid-derived suppressor cells.
Market capitalization (15-Sept-2020)
Closing stock price (15-Sept-2020)
When was BioInvent founded?
BioInvent was founded in 1997.
Who are BioInvent key executives?
BioInvent's key executives are Martin Welschof and Kristoffer Rudenholm Hansson.
How many employees does BioInvent have?
BioInvent has 72 employees.
Who are BioInvent competitors?
Competitors of BioInvent include Cellectar Biosciences, A&G Pharmaceutical and Isotopen Technologien Munchen.
Where is BioInvent headquarters?
BioInvent headquarters is located at The Gamma Building Sölvegatan 41, Lund.
Where are BioInvent offices?
BioInvent has an office in Lund.
How many offices does BioInvent have?
BioInvent has 2 offices.
Receive alerts for 300+ data fields across thousands of companies